Clinical Trials Browser

Phase 2 × Carboplatin × Genitourinary × Clear all

NCT06632977 2026-04-07

PREDICT

Phase 2 Recruiting

Prostatic Neoplasms

NCT04709276 2026-04-06

CHAMP

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 2 FDA

Metastatic Urothelial Cancer

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2 Recruiting

Wilms Tumor

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Phase 2 Active not recruiting

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT02955082 2026-02-04

BARCODE2

Phase 2 Active not recruiting

Hormone Refractory Prostate Cancer

NCT05806515 2026-01-29

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Phase 2 Recruiting

Prostatic Neoplasms

NCT03937843 2026-01-20

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Phase 2 Active not recruiting

Testicular Neoplasms, Seminoma

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Phase 2 Recruiting

Prostatic Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05975307 2025-12-01

BCIRT-01

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03517969 2025-10-20

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

73 enrolled 14 charts

Prostatic Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06738303 2025-08-27

CATCH-177

Phase 2 Recruiting

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04038502 2025-08-20

COBRA

Phase 2 Recruiting

Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07043972 2025-07-20

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Phase 2 Recruiting

Carcinoma, Transitional Cell

NCT05005728 2025-07-17

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Phase 2 Terminated

ATM Gene Mutation

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2 Terminated

6 enrolled 12 charts

Urinary Bladder Neoplasms

NCT00936936 2024-08-26

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Phase 2 Completed

64 enrolled 10 charts

Testicular Neoplasms

NCT05563558 2024-06-11

PEAPOD_FOS

Phase 2 Recruiting

Prostate Cancer Metastatic

NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Phase 2 Completed

49 enrolled 15 charts

Metastatic Urothelial Cancer

NCT03934840 2024-02-28

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Phase 2 Completed

40 enrolled 18 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03390595 2023-10-18

INDUCOMAIN

Phase 2 Completed

Carcinoma, Transitional Cell

NCT03737123 2023-09-13

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

6 enrolled 18 charts

Carcinoma, Transitional Cell

NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Phase 2 Terminated

7 enrolled 9 charts

GenitourinarySarcoma

Bladder Adenocarcinoma

NCT00077129 2023-06-18

Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02598895 2022-11-17

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Phase 2 Completed

14 enrolled 8 charts

Prostatic Neoplasms

NCT00432094 2022-05-17

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Phase 2 Completed

23 enrolled 11 charts

GenitourinaryGynecologic

Ovarian Germ Cell Cancer, Ovarian Neoplasms, Teratoma, Testicular Neoplasms, Carcinoma, Embryonal, Seminoma, Endodermal Sinus Tumor

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Phase 2 Unknown

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT02985021 2021-08-05

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Phase 2 Terminated

2 enrolled 5 charts

Prostatic Neoplasms

NCT02860819 2021-03-03

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Phase 2 Completed

Testicular Neoplasms

NCT01051570 2020-12-01

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Phase 2 Completed

26 enrolled 9 charts

Prostatic Neoplasms

NCT00049257 2020-09-01

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2 Completed

58 enrolled 9 charts

Prostatic Neoplasms

NCT00514540 2020-09-01

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Phase 2 Completed

121 enrolled 8 charts

Prostatic Neoplasms

NCT02311764 2020-01-23

PRO-PLAT

Phase 2 Terminated

Prostatic Neoplasms

NCT02665039 2019-10-08

VINGEM

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01191892 2019-05-16

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00467051 2018-08-29

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Phase 2 Completed

20 enrolled 8 charts

GenitourinaryGynecologic

Ovarian Germ Cell Cancer, Testicular Neoplasms, Carcinoma, Embryonal, Endodermal Sinus Tumor

NCT00002943 2018-08-10

Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

Phase 2 Completed

GenitourinaryGynecologic

Testicular Germ Cell Tumor, Ovarian Neoplasms, Testicular Neoplasms

NCT00461851 2017-12-14

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

Phase 2 Completed

17 enrolled 10 charts

Urinary Bladder Neoplasms